2022
PD01-09 PROTEOGENOMIC AND CLINICAL IMPLICATIONS OF RECURRENT SPLICE VARIANTS IN CLEAR CELL RENAL CELL CARCINOMA
Chang A, Stewart P, Chakiryan N, Soupir A, Tian Y, Du D, Teer J, Kim Y, Spiess P, Chahoud J, Zhang Y, Koomen J, Berglund A, Robinson T, Wang L, Manley B. PD01-09 PROTEOGENOMIC AND CLINICAL IMPLICATIONS OF RECURRENT SPLICE VARIANTS IN CLEAR CELL RENAL CELL CARCINOMA. Journal Of Urology 2022, 207: e33. DOI: 10.1097/ju.0000000000002516.09.Peer-Reviewed Original Research
2020
PD39-06 POOR RESPONSE TO IMMUNOTHERAPY IS ASSOCIATED WITH HIGH EXPRESSION OF A NOVEL EPIDERMAL GROWTH FACTOR RECEPTOR SPLICE VARIANT IN PATIENTS WITH RENAL CELL CARCINOMA
Hajiran* A, Kim Y, Zaman S, Madanyake T, Robinson T, Falasiri S, Spiess P, Kohli M, Boyle T, Mulé J, Teer J, Manley B. PD39-06 POOR RESPONSE TO IMMUNOTHERAPY IS ASSOCIATED WITH HIGH EXPRESSION OF A NOVEL EPIDERMAL GROWTH FACTOR RECEPTOR SPLICE VARIANT IN PATIENTS WITH RENAL CELL CARCINOMA. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000918.06.Peer-Reviewed Original Research
2019
Outcomes in Brain Metastatic Renal Cell Carcinoma Treated with Stereotactic Radiation Therapy and Nivolumab
Mohammadi H, Tolpin A, Peacock J, Oliver D, Sim A, Palm R, Ahmed K, Liu J, Tran N, Etame A, Robinson T, Yu M. Outcomes in Brain Metastatic Renal Cell Carcinoma Treated with Stereotactic Radiation Therapy and Nivolumab. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e82. DOI: 10.1016/j.ijrobp.2019.06.2349.Peer-Reviewed Original Research